EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL

Motohiro Kato iD, Yasuhiro Okamoto iD, Toshihiko Imamura, Akiko Kada iD, Akiko M Saito iD, Yuka Iijima-Yamashita iD, Takao Deguchi iD, Kentaro Ohki iD, Takashi Fukushima, Kenichi Anami, Masashi Sanada iD, Tomohiko Taki und 15 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco.24.00811 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Motohiro Kato und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework. PATIENTS AND METHODS Patients age 1-19 years with newly diagnosed B-ALL were enrolled in this study. These patients were stratified into standard-risk (SR), intermediate-risk (IR), and high-risk (HR) groups. Randomized comparisons assessed the effectiveness of vincristine (VCR)/dexamethasone pulses in the SR group, evaluated the effects of L-asparaginase (ASP) intensification in the IR group, and compared standard consolidation including block-type treatment with experimental consolidation with high-dose methotrexate (HD-MTX) intensified with VCR and ASP in the HR group. RESULTS Of 1,936 patients enrolled, 1,804 were eligible for the experimental treatment. The overall 5-year event-free survival and overall survival rates were 85.2% (95% CI, 83.5 to 86.8) and 94.3% (95% CI, 93.1 to 95.3), respectively. The cumulative incidence of relapse and postremission nonrelapse mortality was 13.2% (95% CI, 11.6 to 14.8) and 0.6% (95% CI, 0.3 to 1.0), respectively. Random assignment in the SR group showed no significant benefit from pulse therapy. In the IR group, ASP intensification had limited effects. In the HR group, standard block therapy and HD-MTX yielded equivalent outcomes. CONCLUSION The ALL-B12 trial achieved favorable outcomes in a nationwide cohort by stratifying treatment on the basis of risk and balancing treatment intensity. This study not only demonstrated that existing standard of care can be further refined but also indicated that improvement in outcomes with intensified chemotherapy has reached a plateau.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansMethotrexateAsparaginaseDexamethasoneChildVincristineChild, PreschoolAdolescentFemaleInfantMaleYoung Adult

Substanzen

MethotrexateAsparaginaseDexamethasoneVincristine

Autor:innen und Institutionen

  • Department of Pediatrics, The University of Tokyo, Tokyo, Japan.
  • Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
  • Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Motohiro Kato, Yasuhiro Okamoto, Akiko Kada, Akiko M Saito, Yuka Iijima-Yamashita, Takao Deguchi, Kentaro Ohki, Masashi Sanada, Nobutaka Kiyokawa, Yuki Yuza, Kenichiro Watanabe, Chihaya Imai, Keizo Horibe, Atsushi Manabe, Katsuyoshi Koh

Zitieren

APA

Kato, M., Okamoto, Y., Imamura, T., Kada, A., Saito, A. M., Iijima-Yamashita, Y., Deguchi, T., Ohki, K., Fukushima, T., Anami, K., Sanada, M., Taki, T., Hashii, Y., Inukai, T., Kiyokawa, N., Kosaka, Y., Yoshida, N., Yuza, Y., Yanagimachi, M., …, & Koh, K. (2025). JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00811

Vancouver

Kato M, Okamoto Y, Imamura T, Kada A, Saito AM, Iijima-Yamashita Y, et al. JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. Journal of Clinical Oncology. 2025. doi:10.1200/jco.24.00811

BibTeX
@article{Kato2025,
  author = {Kato, Motohiro and Okamoto, Yasuhiro and Imamura, Toshihiko and Kada, Akiko and Saito, Akiko M and Iijima-Yamashita, Yuka and Deguchi, Takao and Ohki, Kentaro and Fukushima, Takashi and Anami, Kenichi and Sanada, Masashi and Taki, Tomohiko and Hashii, Yoshiko and Inukai, Takeshi and Kiyokawa, Nobutaka and Kosaka, Yoshiyuki and Yoshida, Nao and Yuza, Yuki and Yanagimachi, Masakatsu and Watanabe, Kenichiro and Sato, Atsushi and Imai, Chihaya and Taga, Takashi and Adachi, Souichi and Horibe, Keizo and Manabe, Atsushi and Koh, Katsuyoshi},
  title = {JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.24.00811}
}
Kostenlos starten →